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Protein glycosylation is an important epigenetic modifying process affecting expression,
localization, and function of numerous proteins required for normal immune function.
Recessive germline mutations in genes responsible for protein glycosylation processes
result in congenital disorders of glycosylation and can have profound immunologic
consequences. Genetic mutations in immune signaling pathways that affect glycosylation
sites have also been shown to cause disease. Sugar supplementation and in vivo
alteration of glycans bymedication holds therapeutic promise for some of these disorders.
Further understanding of how changes in glycosylation alter immunity may provide novel
treatment approaches for allergic disease, immune dysregulation, and immunodeficiency
in the future.
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Introduction
Glycans are biologically important sugars, whichmay be singlemonosaccharides or oligosaccharides
present as branched structures.Most commonly, glycans are linked covalently via glycosidic linkages
to either nitrogen provided by an asparagine residue (N-linked glycans) or by oxygen from serine
or threonine residues (O-linked glycans). Glycosylation of the human proteome is estimated to
be at least 40% and glycans can comprise up to 90% of the total molecular weight of certain
glycoproteins (1, 2). At least 2% of the genome is dedicated to creating, curating, maintaining, and
recognizing glycans, and the loss of any component of these processes can result in dire consequences
or incompatibility with life (3). To date, over 100 recessive Mendelian disorders resulting from
hypomorphic mutations in glycosylation pathways have been identified, which result in the group
of diseases known as congenital disorders of glycosylation (CDGs) (4). It is important to note that
while approximately 2% of the genome encodes the requisite proteins needed for normal glycosy-
lation, glycan structures themselves are not encoded. Therefore, glycans are an important form of
post-translational modification and an epigenetic mechanism that can regulate gene expression.
Derangements in glycosylation patterns can occur inmultiple ways and contribute to the complex
clinical phenotypes seen inCDGs. Specific glycosylation patterns are required for the normal activity
of many immune molecules. Changes in patterns of glycosylation may lead to impaired protein
expression, altered protein ligand function, and significant alterations in immune pathway signaling.
The impact of glycans on specific immune molecules has been studied extensively in model
systems (5, 6). However, the global effect of defective glycosylation on immune function is less well
characterized. This review will explore glycan biology in the context of immune function, describe
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known immunodeficiency syndromes resulting from disordered
glycosylation, and discuss the potential for clinical manipulation
of glycosylation patterns in patients using enzymatic inhibitors
and sugar supplementation.
Glycans
It is useful to group glycans into basic categories, which gen-
erally compartmentalize with localization and function. While
additional glycoforms and important exceptions exist to these
generalizations, a basic understanding of the roles of specific
linkages and glycans will serve to instruct the remainder of this
review.
N-Linked
N-linked glycosylation is the most common form of covalent
protein modification in human cells and is commonly found on
secretory and membrane-bound glycoproteins. N-linked glycans
are so-named because the sugars are covalently linked to nitro-
gen groups on asparagine residues of proteins when present in
a consensus amino acid sequence (Asn-X-Ser/Thr). There are
three general classes ofN-glycans: oligomannose (high-mannose)
type, complex type, and hybrid type. All share a common
pentasaccharide (five sugar) core. The oligomannose type only has
mannose residues attached to the core, the complex type has only
N-acetylglucosamine (GlcNAc), which results in branching from
the core, and the hybrid type contains both mannose and GlcNAc
(2) (Figure 1A).
The process of creating N-linked glycans begins on the cyto-
plasmic surface of the endoplasmic reticulum (ER) where GlcNAc
is attached to the lipid carrier molecule dolichol. Following com-
pletion, the glyan core is transferred to the ER lumen where the
requisite 14-sugar oligosaccharide precursor (Glc3Man9GlcNac2)
is completed (Figure 1A). This structure is then transferred en
bloc to a nascent peptide chain containing the consensus sequence.
Subsequent glycan remodeling begins in the ER: glucose residues
are removed, as are a variable number of the mannose residues.
Removal of these residues occurs during the protein folding cycle,
which is guided by a host of molecular chaperones (7). N-glycans
facilitate proper protein folding by enhancing polypeptide solu-
bility and by recruiting the lectin chaperones calnexin and cal-
reticulin. Misfolded proteins are recognized by their expression
of a specific N-glycan (terminal α1,6-linked mannose) struc-
ture contributing to ER stress and the unfolded protein response
(UPR) (8). When a disordered polypeptide segment is identified,
the terminally misfolded glycoprotein is retro-translocated to the
FIGURE 1 | Glycan structures. (A) Representative examples of N-glycans
increasing in complexity from left to right. Far left is the 14-sugar precursor
(Glc3Man9GlcNac2) with conserved core (indicated in red dashed box). This
structure is transferred en bloc from dolichol to asparagine (Asn) to form other
N-glycans. Increasing branching and complexity is enabled by addition of
GlcNAc to the core structure. (B) Representative example of an O-glycan
structure; no conserved core exists. (C) Sialyl-Lewis-X (sLex) structure that
would be frequently found at the terminus of poly-N-acetyllactosamines.
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cytoplasm where it is targeted for ubiquitination and proteasomal
degradation, a process called endoplasmic-reticulum-associated
protein degradation (ERAD) (9). If folding properly occurs, the
glycoprotein is transited to the Golgi where additional man-
nose residues may be removed and multiple additional sugars
(GlcNAc, galactose, fucose, sialic acid) and othermoieties (sulfate,
phosphate) may be added. The complete glycoproteins are then
trafficked to their ultimate destinations.
O-Linked
In contrast to N-linked glycans, O-linked glycans are formed once
the protein has transited to the Golgi, and occur by step-wise
addition of monosaccharides. Formation occurs by the covalent
addition of primarilyN-acetylgalactosamine (GalNAc) to the oxy-
gen group present on serine (Ser) or threonine (Thr) residues
(Figure 1B). A variety of different core structures for O-glycans
have been described based upon initial and subsequent sugar
addition. Many large intracellular glycoproteins contain O-linked
glycans, but membrane-bound and secreted proteins may also
contain these residues (2).
O-GlcNAc Modification
Within the cytoplasm and nuclear compartments, a distinct form
of glycosylation called O-GlcNAcylation may also occur. It is
distinguished by the nature and cellular location of sugar addi-
tion. The amino-sugar uridine diphosphate N-acetylglucosamine
(UDP-GlcNAc) provides the substrate for O-linked addition of
single GlcNAc molecules at Ser and Thr residues (10). Addi-
tion of GlcNAc in this context functions much like a phosphate
group; it is transient, may be added and removed multiple times,
and generally exists only as a single sugar. Similar to the way
in which protein phosphorylation may affect protein activation,
O-GlcNAc addition may compete with phosphorylation, and fol-
lowing addition to acceptor sites byO-GlcNAc transferase (OGT)
can alter protein activity without affecting subcellular localization
or phosphorylation state (11).
Sialyl-Lewis-X
A common outer structural element on both N- and O-glycans
is the sub-terminal disaccharide N-acetyllactosamine (LacNAc).
In the Golgi, these disaccharides can be added at multiple sites
of glycans resulting in poly-N-acetyllactosamines (frequently
called polylactosamine). The outer LacNAc residues are frequently
capped by sialic acid residues. Subsequent fucosylation gives rise
to the sialyl-Lewis-X (sLex) motif (Figure 1C), which facili-
tates cell–cell interactions by providing an important ligand for
Selectins, mediating processes such as intercellular adhesion (12).
Congenital Disorders of Glycosylation
Numerous biologic functions are dependent on glycans and a
complete loss of function in any step required for glycan for-
mation is frequently incompatible with life, though in some
cases compensatory mechanisms exist (4). Recessive hypomor-
phic mutations in any step may likewise result in a CDG. Geno-
type–phenotype correlations in these disorders are often incon-
sistent and difficult to establish. In part, because of the variability
and complex nature of the phenotypes seen in CDGs, this group of
disorders has only been recognized clinically in the past 30 years.
Currently, there are over 100 known CDGs affecting virtually
every step of glycan synthesis, transfer, and curation and they have
been assembled into two basic groups. By historical convention,
type I defects result from impaired glycan formation. Patients with
type I disorders are characterized by the absence of N-glycans
(specifically sialic acid residues) at consensus sequences. These
may be detected clinically by mass spectroscopic evaluation of
glycan patterns on serum transferrin, which contains two such
consensus sequences. Type II disorders result from a failure to
trim or appropriately curate glycans once they have been added to
target proteins or lipids. When evaluating serum proteins in these
disorders, the majority of N-glycosylation sites are occupied, but
glycan complexity and diversity are altered (13).
Glycosylation is Critical to Normal Immune
Function
In addition to mechanisms broadly important to immunity such
as cell–cell adhesion and signal transduction, several specific
innate and adaptive immunologic pathways have demonstrated a
dependence on appropriate glycosylation.
Innate Immunity
Glycoproteins are critical for normal cell–cell interactions. This
is perhaps most apparent in leukocyte trafficking (14). In the
context of an inflammatory response, the first step of mobilizing
cells to sites of inflammation involves rolling on the vascular
endothelium. This process is mediated by the glycan ligand sLex
and the C-type lectin receptors Selectins (12). Absence of sLex, as
seen in patients with SLC35C1mutations, results in impairment of
this process and leukocyte adhesion deficiency type 2 (discussed
separately) (15). In addition to sLex, other glycoprotein ligands for
the Selectins are important to leukocyte homing and trafficking
exist and include GlycCAM1, P-selectin glycoprotein ligand 1
(PSGL1), and αMβ2 integrin (16).
Toll-like receptors, cytokines, and cytokine receptors also
comprise glycoproteins and have multiple N-glycosylation sites
(17, 18). Experimentally disrupting glycosylation sites on these
glycoproteins has demonstrated that expression and/or func-
tion is reduced or abolished in vitro when glycan expression
is altered. Both loss of glycans at predicted sites and gain of
novel glycan consensus sites have been shown to result in altered
signaling (19, 20).
In a study examining all reported variants in the Human Gene
Mutation Database, it was found that approximately 1% of muta-
tions present created new N-glycan consensus sequences. The
potential impact of this finding was demonstrated among patients
with mutations in Mendelian susceptibility to mycobacterial dis-
ease (MSMD) caused by interferon-gamma receptor 2 (IFN-γR2)
insufficiency (21). A protein positive IFNGR2mutation identified
in three patients withMSMD resulted in the addition of a glycosy-
lation site by creating an additional N-glycan consensus sequence
(T168N). Other mutations in IFNGR2 have also been reported to
result in disordered N-glycosylation through unclear mechanisms
(R114C, S124F, G141R, and G227R). Remarkably in all cases,
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in vitro cellular responses to IFN-γ were improved by exogenous
N-glycan modification. Similar mutations resulting in N-glycan
perturbations in type I cytokine receptors have also been reported.
Suchmutations in granulocyte colony-stimulating factor (G-CSF)
receptor and interleukin-21 receptor (IL-21R) have been shown
to cause severe congenital neutropenia (SCN) and a combined
immunodeficiency syndrome, respectively (22, 23).
Adaptive Immunity
Glycans appear to dictate multiple aspects of adaptive immu-
nity affecting both T cells and B cells. Beginning early in T cell
ontogeny, glycans appear to regulate fate decisions and diversity
(24–27). The C-type lectin galectin-1 expressed in the thymus
modulates T cell receptor (TCR) signal strength and contributes
to negative selection (28). Antigen receptors on T cells (TCR)
and B cells (BCR), as well as major histocompatibility complex
(MHC)molecules are likewise glycoproteins (26). In mouse mod-
els employing tetramers, alteration in specific glycan motifs has
been shown to have significant effects in skewing TCR repertoires
(29). The T cell co-receptors CD4 and CD8, and several other
molecules critical in dictating T cell fates including CTLA-4 and
Notch receptors, are glycoproteins and their expression and func-
tion are dependent upon normal glycosylation.Understanding the
specific contribution that altered glycosylation may have on T cell
differentiation in vivo is an active area of investigation.
In addition to the effect glycans have on antigen receptor signal-
ing, immunoglobulin activity following class-switch recombina-
tion is also a glycan dependent process. Immunoglobulin G (IgG),
IgE, and IgA all contain glycosylation sites that dictate receptor
binding thus affecting trafficking and function (30). Alterations
of glycan composition have been shown to dramatically alter IgG
half-life in vitro and in vivo (31, 32). In humanized animal models,
alternative glycosylation motifs in the Fc groove of IgG also result
in non-canonical signaling and have implications in IgG effector
function (33).
Immune Consequences of Altered
Glycosylation
Given that expression and function of numerous critical immune
molecules are dependent on normal glycosylation; one might
predict that there would be multiple primary immunodeficiency
diseases (PIDDs) caused by defective glycosylation.While work to
extensively immunophenotype CDG patients continues, we will
discuss several PIDDs already identified resulting from glycosyla-
tion defects (Table 1; Figure 2).
SLC37A4 and G6PC3 Deficiencies
Glucose-6-phosphatase, catalytic, 3 (G6PC3) encodes the cat-
alytic subunit of glucose-6-phosphatase-β (G6Pase), a ubiqui-
tously expressed ER-resident protein. This enzyme is critical for
liberating free glucose, catalyzing the final step of gluconeogenesis
and glycogenolysis (34). G6Pase activity is dependent upon sub-
strate – G6P within the ER – supplied by the glucose-6-phosphate
transporter 1 (G6PT1) (35). G6PT1 is encoded by solute carrier
family 37, member 4 (SLC37A4). Autosomal recessive mutations
in G6PC3 and SLC37A4 both result in similar forms of SCN
characterized by susceptibility to severe bacterial and fungal infec-
tions. At least seven different homozygous damaging mutations
inG6PC3 among Turkish, Greek, Arab, Persian, and German kin-
dreds have been identified (36–40). Intermittent thrombocytope-
nia, cardiac defects, prominent superficial veins, microcephaly,
and sensorineuronal hearing loss have also been associated with
these mutations (41). In humans, G6PC3-deficient neutrophils
appear dysfunctional and demonstrate evidence of ER stress, with
enhanced propensity toward apoptosis (42). In addition to SCN,
mutations in SLC37A4 cause glycogen storage disease (type Ib)
characterized by hypoglycemia, hepatomegaly, hyperlipidemia,
growth failure, hyperuricemia, inflammatory bowel disease, and
lactic acidosis (43). Loss of either G6PC3 or SLC37A4 results
in reduced glycosylation of the NADPH oxidase system, as well
as a reduction in N- and O-glycan complexity characterized by
truncation of complex branching sugars (44). Whether this is due
to lack of substrate or metabolic failure remains to be determined.
PGM3 Deficiency
Recently, autosomal recessive hypomorphic mutations in
phosphoglucomutase-3 (PGM3) were identified in nine kindreds
by three independent groups (45–47). The clinical phenotype
described was quite broad potentially representing the degree of
impairment in enzymatic function. Absent Pgm3 is embryonically
lethal in mice and predicted to be incompatible with life in
TABLE 1 | Inherited glycosylation defects resulting in immune dysfunction.
Gene Protein Glycosylation defect Immune defect
G6PC3 Glucose-6-phosphatase-β N-glycan and O-glycan complexity Neutropenia
SLC37A4 Glucose-6-phosphate transporter 1 N-glycan and O-glycan complexity Neutropenia
PGM3 Phosphoglucomutase 3 N-glycan and O-glycan expression Combined immunodeficiency; neutropenia; atopy
PMM2 Phosphomannomutase 2 N-glycan expression Neutrophil chemotaxis; humoral responses
ALG1 Beta-1,4-mannosyltransferase N-glycan expression Humoral immunodeficiency
ALG12 Alpha-1,6-mannosyltransferase N-glycan expression Humoral immunodeficiency
MOGS Mannosyl-oligosaccharide glucosidase N-glycan complexity Low immunoglobulins; reduced susceptibility to
N-glycosylated enveloped viruses
SLC35A1 CMP-sialic acid transporter Global sialylation Neutropenia
O-mannosylationa
SLC35C1 GDP-fucose transporter 1 Global fucosylation Leukocyte trafficking
JAGN1 Jagunal homolog1 N-glycan fucosylation Neutropenia
aO-mannosylation defect demonstrated on α-dystroglycan in vitro.
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FIGURE 2 | Glycosylation pathway defects with known immunologic
consequences. (A) Simplified scheme demonstrating N-linked glycosylation
and 10 known gene defects resulting in altered glycosylation and
immunologic disease; dashed arrows indicate presence of non-depicted
enzymatic steps; question marks depict theoretical blocks for which the
mechanistic defect remains speculative. N-glycan formation begins in the
cytoplasm (left) where phosphoglucomutase 3 (PGM3) and
phosphomannomutase 2 (PMM2) provide key sugar substrate and
beta-1,4-mannosyltransferase (ALG1) adds the first mannose. The core
glycan is transferred to the ER lumen where alpha-1,6-mannosyltransferase
(ALG12) adds an additional mannose and glucose-6-phosphate transporter 1
(SLC37A4) and glucose-6-phosphatase-β (G6PC3) potentially affect
availability of glucose to complete the 14-sugar precursor (Glc3Man9
GlcNac2). Following transfer of the growing glycan to a nascent protein,
mannosyl-oligosaccharide glucosidase (MOGS) participates in glycan
remodeling prior to transit of the glycoprotein to the Golgi, a process
facilitated in part by jagunal homolog1 (JAGN1). In the Golgi CMP-sialic acid
transporter (SLC35A1) and GDP-fucose transporter 1 (SLC35C1) provide
additional sugar substrate to complete complex N-glycan formation.
(B) Reduced branching N-glycan pattern seen in patients with PGM3
deficiency (blue) detected using a fluorescently labeled lectin (L-PHA) to
quantitate expression on lymphocytes by flow cytometry (green, unstained;
red, control). (C) Schematic depiction of HIV infection initiation requiring the
interaction of several glycoproteins (CD4, gp120 trimer, and gp41 trimer).
Reduced complexity of N-glycans seen in MOGS deficiency, as depicted by
the presence of high-mannose residues in this figure, results in impaired viral
entry, and reduced infectivity of newly formed virions in vitro. (D) Depiction of
impaired leukocyte trafficking due to reduced sialyl-Lewis-X (sLex) binding to
E-selectin. SLC35C1 mutations result in leukocyte adhesion deficiency, type
2 (LAD2), and mutations in SLC35A1 result in impaired sLex expression on
neutrophils (indicated by red X). In LAD2, this results in a leukocyte trafficking
defect in patients and impaired immunity.
humans (48). Hypomorphic Pgm3 function in mice results in
a bone marrow failure phenotype and a similar phenotype was
observed among three patients harboring deleterious PGM3
mutations, who presented early in life with T B NK+ severe
combined immunodeficiency (SCID). Two patients underwent
hematopoietic stem cell transplant (HSCT) – one received
6/6 HLA-matched cord blood at 4months of age, the other
underwent HLA-identical sibling-mobilized peripheral blood
stem cell transplantation at 6 years of age. Both had successful
engraftment and the patients were healthy 14 and 6months
out from transplant at the time of publication. In addition to
a SCID phenotype, compound heterozygous and homozygous
hypomorphic mutations were identified among six families
presenting with a hyper-IgE phenotype, characterized by
moderate to severe atopic dermatitis, significant elevations in IgE
and connective tissue abnormalities; dysmorphic appearance and
Frontiers in Pediatrics | www.frontiersin.org June 2015 | Volume 3 | Article 545
Lyons et al. Glycans instructing immunity
neurocognitive impairment were also common to all three patient
cohorts. Unique to PGM3-deficient patients with hyper-IgE
phenotypes was an increase in Th17 cells and autoimmunity.
PGM3 normally interconverts GlcNAc-1-phosphate and
GlcNAc-6-phosphate. The fundamental defect in PGM3
deficiency appears to be just downstream with a failure in
normal UDP-GlcNAc formation. UDP-GlcNAc is a critical
nucleotide-sugar that provides the GlcNAc substrate for N- and
O-linked glycosylation as well as O-GlcNAc modification, thus
making this a type I CDG. In the absence of adequate GlcNAc, a
failure to form the core N-glycan would be predicted, and indeed
reduced N-glycans were demonstrated in these patients. Further
work is underway to better characterize defects in O-glycans and
O-GlcNAc modification, and to understand the specific pathways
being affected, which lead to such profound immunophenotypes.
PMM2 Deficiency
In the steps following GlcNAc addition during core N-glycan
formation, mannose (Man) residues are added from UDP-
Man in a manner similar to UDP-GlcNAc. PMM2 encodes
phosphomannomutase-2, an enzyme analogous to PGM3, which
interconverts Man-6-phosphate to Man-1-phosphate. Failure in
this step due to autosomal recessive mutations in PMM2 results
in insufficient mannose substrate and CDG-Ia, the most common
CDG, also known as Jaeken syndrome (49). Presentation may
be quite variable. Some patients present in infancy with a severe
multi-system syndrome comprised of neurologic impairment, GI
disease, and failure to thrive, while other patients survive well
into adulthood but demonstrate intellectual disability, associ-
ated with neurologic, musculoskeletal, and endocrine defects. Of
those patients presenting early in childhood, a high mortality is
observed in the first year of life, and infection is themost common
cause. Because of this finding, a systematic immune evaluation of a
cohort of CDG-Ia patientswas undertakenwhich revealed impair-
ment in neutrophil chemotaxis and poor vaccine responses among
affected individuals (50). Clinical improvement as measured by a
reduced incidence of infection was observed when patients were
placed on intravenous immunoglobulin (IVIG) replacement.
ALG1 and ALG12 Deficiencies
Just as insufficient substrate for mannosylation caused by
PMM2 mutations results in immunologic sequelae, impaired
enzymatic activity limiting mannosylation directly, results in
a similar clinical phenotype. Asparagine-linked glycosylation
1 homolog (ALG1) encodes beta-1,4-mannosyltransferase, the
enzyme responsible for addition of the first mannose residue to
the growing coreN-glycan (Figure 1A). Autosomal recessive loss-
of-function mutations in ALG1 result in CDG-Ik, characterized
by dysmorphic features, neurologic impairment, and humoral
deficiency characterized by decreasedB cells andundetectable IgG
in the context of severe protein loss (due to nephrotic syndrome
in one patient, and GI losses in another) (51–54). Asparagine-
linked glycosylation 12 homolog (ALG12) encodes alpha-1,6-
mannosyltransferase, the enzyme responsible for adding the
eighthmannose residue to the coreN-glycan. Damaging recessive
mutations in ALG12 result in CDG-Ig, characterized by dys-
morphia, psychomotor retardation, failure-to-thrive, male genital
hypoplasia, low IgG, and humoral deficiency complicated by
recurrent bacterial infections (55).
MOGS Deficiency
Within the ER after GlcNAc and Man residues are added to the
core N-glycan, glucose is added to cap and complete its pro-
duction. The next step in glycan processing involves removal
of these terminal glucose residues by mannosyl-oligosaccharide
glucosidase (MOGS). Failure to remove terminal glucose residues
is seen in patients with autosomal recessive damaging mutations
in MOGS, resulting in CDG-IIb (56). Clinically, the patients
display developmental, neurologic, and musculoskeletal defects.
The enzymatic defect leads to accumulation of high-mannose-
type N-glycans and a failure to form complex-type N-glycans
(normal structures shown in Figure 1A) with profound immuno-
logic outcomes (31). Patients exhibit hypogammaglobulinemia
due to a significantly reduced IgG half-life. Despite these impair-
ments, patients do not have an increase in clinical infections, and
are paradoxically protected from N-glycosylated enveloped virus
infections as a consequence of abnormal glycoprotein expression
and formation.
SLC35A1 Deficiency
The common outer structural element of sLex is created by
fucosylation of sialic acid capped poly-N-acetyllactosamines (as
described above and shown in Figure 1C). Also, as previously
discussed, Selectins recognize this motif and bind to it facili-
tating the first step in leukocyte trafficking. For sialylation to
occur, the sugar nucleotide precursor cytosine-5-monophospho
(CMP)-sialic acid must be transported into the ER. Solute carrier
family 35, member 1 (SLC35A1) encodes the CMP-sialic acid
transporter that accomplishes this. CDG-IIf is caused by auto-
somal recessive loss-of-function mutations in SLC35A1 (57). To
date, one patient has been reported with damaging heterozygous
mutations in SLC35A1 presenting with a syndrome character-
ized by neutropenia, macrothrombocytopenia, recurrent invasive
bacterial infection and hemorrhage. Complete absence of sLex
was reported on patient neutrophils as well; however, in vitro
trafficking and responses appeared unaffected. The patient under-
went bone marrow transplantation at 34months, and died from
refractory respiratory failure at 37months following a complicated
course, which included graft-versus-host disease and pulmonary
hemorrhage.
SLC35C1 Deficiency (Leukocyte Adhesion
Deficiency, Type 2)
As mentioned, fucosylation of sialic acid residues is required
for sLex formation. The GDP-fucose transporter, which provides
substrate for this addition (also called fucosyltransferase I), is
encoded by SLC35C1. The transporter is located on themembrane
of the Golgi where it normally functions to move cytosolic GDP-
fucose into the Golgi lumen to act as a substrate for fucosylation
of developing glycans. Loss of this transporter due to autosomal
recessive mutations results in leukocyte adhesion deficiency, type
2 (LAD2), also known as CDG-IIc. These patients demonstrate
a failure to appropriately fucosylate glycans and cannot make
sLex. Patient leukocytes are unable to appropriately reach sites of
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infection, resulting in recurrent severe bacterial infections with
the hallmark of neutrophilia and little or absent purulence at the
infected site (15). As with other CDGs the clinical phenotype is
variable and complex, but can include neurologic and develop-
mental deficits, as well as dwarfism. Fucosylation also plays an
important role inABOblood group determinant and patientswith
this syndrome exhibit the Bombay blood group type.
JAGN1 Deficiency
Impaired fucosylation has also been identified among individuals
with autosomal recessive loss-of-function mutations in jagunal
homolog 1 (JAGN1). Fourteen patients from nine families have
been identified with homozygous JAGN1 mutations, resulting
in SCN (type 6) (58, 59). Both maturational arrest of myeloid
precursors in the bonemarrow and enhanced apoptosis were seen
in patient neutrophils. JAGN1 encodes a ubiquitously expressed
protein that localizes to the ER and participates in protein traffick-
ing. Complete knockout of Jagn1 is embryonically lethal in mice.
For unclear reasons, disruption of this protein results in abnormal
N-glycosylation. Defective fucosylation on branching N-glycans
was identified both in JAGN1-deficient human neutrophils and
in murine neutrophils carrying a hematopoietic lineage-specific
deletion of Jagn1. However, other blood cells appear to be grossly
unimpaired.
Therapeutic Manipulation of Glycans
Because glycosylation is a post-translational modification, it is
conceivable that some CDGs and immune disorders would be
responsive to treatments that can alter glycans in vivo. There has
been interest in treating CDG patients with excess or alternative
sugar substrate in order to drive or shunt defective pathways and
promote production of the deficient sugar product. While not
all genetic deficiencies previously targeted are associated with
identified immune defects, the approaches have been instructive
and thus are discussed. Medications that alter glycan expression
in patients with intact glycosylation pathways have also been
investigated for use in the treatment of viral infections, and are
briefly discussed.
Fucose Supplementation in LAD2
AmongLAD2patientswith impairedGDP-fucose transport to the
site of sugar addition in the Golgi, oral fucose supplementation
has demonstrated mixed efficacy (60–63). In one cohort, a patient
was administered oral fucose at 25mg/kg, and these doses were
slowly escalated to a maximum of 492mg/kg over approximately
9months of continuous supplementation. Therapy resulted in
normalization of neutrophil counts and sLex, a reduction of inci-
dent infection, and improvement in physical and psychomotor
growth and development (60). In a second cohort, two patients
were given a loading dose of 2.5–5 g, followed by daily supplemen-
tation with 200mg/kg. After 1month, the dose was increased to
1 g/day in five divided doses and continued for 1 year without sig-
nificant improvement in fucosylated protein expression or other
clinical parameters (61). In the latter study, dosing may have been
insufficient to achieve normalization. A fourth patient was treated
with oral fucose at 165mg/kg, increased to 1000mg/kg divided in
five daily doses over approximately 9months. Neutrophil number
and glycan fucosylation were rescued with a reduction in incident
infection. Unfortunately, the success of therapy was tempered by
induction of autoimmune neutropenia with coincident expression
of intact H-antigen on erythrocytes in this individual (63).
Mannose Supplementation in MPI and PMM2
Deficiencies
Mannosphosphate isomerase (MPI) interconverts fructose-6-
phosophate, derived from glucose, and mannose-6-phosphate
providing additional substrate for phosphomannomutase-2
(PMM2). Autosomal recessive defects in MPI, like PMM2
discussed previously, deplete the pool of GDP-mannose available
for glycosylation. MPI deficiency presents in childhood with
protein losing enteropathy, coagulopathy, fibrotic liver disease,
and failure to thrive. In contrast to PMM2 deficiency, neurologic
impairment does not appear to be a feature. A patient with
MPI deficiency was treated with 100mg/kg three times daily,
increased after 8months to 150mg/kg five times daily (64).
Normalization of serum transferrin glycan expression, resolution
of GI bleeding, and resolution of protein losing enteropathy with
normalization of total serum protein was observed. A 5-year
follow-up on this patient demonstrated persistent efficacy of oral
mannose replacement (65). By striking contrast, patients with
PMM2 deficiency, treated for 9 days with 100mg/kg every 3 h,
demonstrated no clinical or laboratory improvement on enteral
mannose therapy (66).
Galactose Supplementation in PGM1 Deficiency
More recently, galactose supplementation has been used in one
cohort of six patients from five kindreds with phosphogluco-
mutase 1 (PGM1) deficiency (67). PGM1 normally intercon-
verts glucose-1-phosphate (Glc-1-P) and glucose-6-phosphate
(Glc-6-P). Glc-1-P can also be enzymatically derived from
galactose-1-phosphate and dietary supplementation with galac-
tose may provide excess substrate to overcome reduced Glc-1-
P resulting from PGM1 deficiency. As with other CDGs, the
clinical phenotype of patients with PGM1 deficiency is variable
and complex, including musculoskeletal abnormalities, growth
and developmental delay, and endocrine abnormalities. Supple-
mentation with 0.5–1.0mg/kg/day of galactose resulted in nor-
malization ofN-glycan expression on serum transferrin and other
serum proteins. Clinical improvement was also reported in two
patients characterized by partial resolution of hypogonadotropic
hypogonadism, cessation of rhabdomyolysis episodes, and no
progression of hepatopathy or cardiac disease.
GlcNAc and Triacetyluridine Supplementation in
PGM3 Deficiency
Among patients with PGM3 deficiency exogenous GlcNAc
in vitro has been demonstrated to restore UDP-GlcNAc levels
in patient fibroblasts, and to partially rescue cellular abnormali-
ties (45). A clinical protocol to provide PGM3-deficient patients
with supplemental GlcNAc and triacetyluridine will likely begin
enrollment in early Summer 2015.
MOGS Inhibitors and Viral Immunity
Mannosyl-oligosaccharide glucosidase inhibitors are one exam-
ple of how manipulation of glycans may provide therapeutic
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benefits in the general population. Whether through co-opting
lectin receptors, such as DC-SIGN, or by canonical protein
receptor–ligand interactions, glycoproteins of enveloped viruses
mediate docking and entry of particles into host cells (68, 69).
In both lectin and protein-based glycoprotein recognition, the
glycan structure is critical to successful infection, as demonstrated
in patients with CDG-MOGS (30). Several MOGS inhibitors
have been developed, and have demonstrated the ability to
reduce viral entry, replication, and virulence in vitro (70–72).
In a clinical trial, patients treated with the MOGS inhibitor
miglustat in combination with zidovudine had lower plasma
viral loads and higher CD4+ T cell counts compared to those
treated with zidovudine alone, without significant side effects
(73). Other drugs that alter glycosylation, such as kifunensine
and nelfinavir, have also displayed therapeutic promise (20, 74).
In the future, additional drugs, which alter glycosylation, may
provide useful primary or adjunctive treatments, or regimens
for prophylaxis, particularly in the context of enveloped viral
infections.
Limitations of Supplementation and Additional
Clinical Approaches
Therapeutic sugar supplementation, while a promising clinical
intervention, remains untested in many CDGs. Because any one
CDG is rare, and each enzymatic deficiency results in a discrete
defect, caution must be taken in generalizing success from one
CDG to another, even within the same pathway (e.g., PMM2 and
MPI). Furthermore, excess sugar substrate from supplementation
may lead to alternate biosynthetic pathway activation. This in turn
may potentially lead to toxic metabolite formation, induction of
autoimmunity, or loss of partial viral protection. Because of these
complex issues, no consensus recommendations exist to guide
therapy at this time.
While no medications currently exist to specifically target
improvement of defective enzymatic activity, enzyme replace-
ment therapy, and gene therapy are under investigation to treat
these disorders, and have shown promise in some immunodefi-
ciency diseases. HSCT has been shown to be effective in treating
SCID caused by PGM3 deficiency. How transplantation in this
compartment may improve disease manifestations in other organ
systems (e.g., neurologic function) remains to be seen.
Conclusion
Altered glycosylation is a well-established feature in many disease
states. Particular glycan patterns are known to be associated with
oncogenesis and tumor progression, as well as a host of illnesses
and pathologic processes occurring later in life, includingmultiple
sclerosis, Alzheimer’s disease, paroxysmal nocturnal hemoglobin-
uria, rheumatoid arthritis, IgA nephropathy, and polycystic liver
disease (75–81). CDGs, the archetypal inherited disorders of
altered glycosylation likewise produce myriad clinical features,
and may result in profound immunologic defects and immunod-
eficiency. Discrete alterations in glycan expression due to muta-
tions in immune molecules (e.g., IFNGR2) have also been shown
to result in primary immunodeficiency. Understanding themech-
anisms by which altered glycans resulting from germline genetic
changes exert their dominant effects on immunologic function
may provide novel approaches for targeting immune defects in the
future. Furthermore, manipulation of glycans by medication or
dietary supplementation may prove beneficial not only to CDG
patients but also to PIDD patients who share common immune
phenotypes.
Acknowledgments
The authors would like to acknowledge and thank Lynne A.Wolfe
for her critique of this manuscript and for her ongoing collabo-
ration. These studies were supported in part by the Intramural
Research Program of the National Institutes of Health (NIH)
Clinical Center and National Institutes of Allergy and Infectious
Diseases (NIAID).
References
1. Gupta R, Brunak S. Prediction of glycosylation across the human proteome
and the correlation to protein function. Pac Symp Biocomput (2002). 310–22.
doi:10.1142/9789812799623_0029
2. Varki A. Essentials of Glycobiology. 2nd ed. (Vol. xxix). Cold Spring Harbor, NY:
Cold Spring Harbor Laboratory Press (2009). 784 p.
3. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and
disease. Cell (2006) 126(5):855–67. doi:10.1016/j.cell.2006.08.019
4. Freeze HH, Chong JX, Bamshad MJ, Ng BG. Solving glycosylation disorders:
fundamental approaches reveal complicated pathways. Am J HumGenet (2014)
94(2):161–75. doi:10.1016/j.ajhg.2013.10.024
5. Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat Rev
Immunol (2008) 8(11):874–87. doi:10.1038/nri2417
6. van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of
innate and adaptive immune responses. Nat Immunol (2008) 9(6):593–601.
doi:10.1038/ni.f.203
7. Helenius A, Aebi M. Intracellular functions of N-linked glycans. Science (2001)
291(5512):2364–9. doi:10.1126/science.291.5512.2364
8. Janssens S, Pulendran B, Lambrecht BN. Emerging functions of the unfolded
protein response in immunity. Nat Immunol (2014) 15(10):910–9. doi:10.1038/
ni.2991
9. Ruggiano A, Foresti O, Carvalho P. Quality control: ER-associated degradation:
protein quality control and beyond. J Cell Biol (2014) 204(6):869–79. doi:10.
1083/jcb.201312042
10. Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins:
signal transduction and O-GlcNAc. Science (2001) 291(5512):2376–8. doi:10.
1126/science.1058714
11. Lewis BA, Hanover JA. O-GlcNAc and the epigenetic regulation of gene
expression. J Biol Chem (2014) 289(50):34440–8. doi:10.1074/jbc.R114.595439
12. Fukuda M, Hiraoka N, Yeh JC. C-type lectins and sialyl Lewis X oligosaccha-
rides. Versatile roles in cell-cell interaction. J Cell Biol (1999) 147(3):467–70.
doi:10.1083/jcb.147.3.467
13. Jaeken J, Hennet T, Matthijs G, Freeze HH. CDG nomenclature: time for a
change! Biochim Biophys Acta (2009) 1792(9):825–6. doi:10.1016/j.bbadis.2009.
08.005
14. Sperandio M, Gleissner CA, Ley K. Glycosylation in immune cell trafficking.
Immunol Rev (2009) 230(1):97–113. doi:10.1111/j.1600-065X.2009.00795.x
15. Gazit Y, Mory A, Etzioni A, Frydman M, Scheuerman O, Gershoni-Baruch
R, et al. Leukocyte adhesion deficiency type II: long-term follow-up and
review of the literature. J Clin Immunol (2010) 30(2):308–13. doi:10.1007/
s10875-009-9354-0
16. Scott DW, Patel RP. Endothelial heterogeneity and adhesion molecules N-
glycosylation: implications in leukocyte trafficking in inflammation. Glycobi-
ology (2013) 23(6):622–33. doi:10.1093/glycob/cwt014
17. Weber AN, Morse MA, Gay NJ. Four N-linked glycosylation sites in human
toll-like receptor 2 cooperate to direct efficient biosynthesis and secretion. J Biol
Chem (2004) 279(33):34589–94. doi:10.1074/jbc.M403830200
18. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Gra-
novsky M, et al. Regulation of cytokine receptors by Golgi N-glycan
Frontiers in Pediatrics | www.frontiersin.org June 2015 | Volume 3 | Article 548
Lyons et al. Glycans instructing immunity
processing and endocytosis. Science (2004) 306(5693):120–4. doi:10.1126/
science.1102109
19. Sun J, Duffy KE, Ranjith-Kumar CT, Xiong J, Lamb RJ, Santos J, et al. Structural
and functional analyses of the human toll-like receptor 3. Role of glycosylation.
J Biol Chem (2006) 281(16):11144–51. doi:10.1074/jbc.M510442200
20. Moncada-Velez M, Martinez-Barricarte R, Bogunovic D, Kong XF, Blancas-
Galicia L, Tirpan C, et al. Partial IFN-gammaR2 deficiency is due to protein
misfolding and can be rescued by inhibitors of glycosylation. Blood (2013)
122(14):2390–401. doi:10.1182/blood-2013-01-480814
21. VogtG, Chapgier A, YangK, ChuzhanovaN, Feinberg J, Fieschi C, et al. Gains of
glycosylation comprise an unexpectedly large group of pathogenic mutations.
Nat Genet (2005) 37(7):692–700. doi:10.1038/ng1581
22. Triot A, Jarvinen PM, Arostegui JI, Murugan D, Kohistani N, Dapena Diaz
JL, et al. Inherited biallelic CSF3R mutations in severe congenital neutropenia.
Blood (2014) 123(24):3811–7. doi:10.1182/blood-2013-11-535419
23. Kotlarz D, Zietara N, Uzel G, Weidemann T, Braun CJ, Diestelhorst J,
et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary
immunodeficiency syndrome. J Exp Med (2013) 210(3):433–43. doi:10.1084/
jem.20111229
24. DanielsMA,Hogquist KA, Jameson SC. Sweet ‘n’ sour: the impact of differential
glycosylation on T cell responses. Nat Immunol (2002) 3(10):903–10. doi:10.
1038/ni1002-903
25. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M,
et al. Complex N-glycan number and degree of branching cooperate to regulate
cell proliferation and differentiation. Cell (2007) 129(1):123–34. doi:10.1016/j.
cell.2007.01.049
26. Wolfert MA, Boons GJ. Adaptive immune activation: glycosylation does matter.
Nat Chem Biol (2013) 9(12):776–84. doi:10.1038/nchembio.1403
27. Zhou RW, Mkhikian H, Grigorian A, Hong A, Chen D, Arakelyan A, et al.
N-glycosylation bidirectionally extends the boundaries of thymocyte positive
selection by decoupling Lck from Ca(2)(+) signaling. Nat Immunol (2014)
15(11):1038–45. doi:10.1038/ni.3007
28. Liu SD, Whiting CC, Tomassian T, Pang M, Bissel SJ, Baum LG, et al. Endoge-
nous galectin-1 enforces class I-restricted TCR functional fate decisions in
thymocytes. Blood (2008) 112(1):120–30. doi:10.1182/blood-2007-09-114181
29. Moody AM, Chui D, Reche PA, Priatel JJ, Marth JD, Reinherz EL. Develop-
mentally regulated glycosylation of the CD8alphabeta coreceptor stalk mod-
ulates ligand binding. Cell (2001) 107(4):501–12. doi:10.1016/S0092-8674(01)
00577-3
30. Hayes JM, Cosgrave EF, Struwe WB, Wormald M, Davey GP, Jefferis R,
et al. Glycosylation and Fc receptors. Curr Top Microbiol Immunol (2014)
382:165–99. doi:10.1007/978-3-319-07911-0_8
31. Sadat MA, Moir S, Chun TW, Lusso P, Kaplan G, Wolfe L, et al. Glycosylation,
hypogammaglobulinemia, and resistance to viral infections. N Engl J Med
(2014) 370(17):1615–25. doi:10.1056/NEJMoa1302846
32. Ishino T, Wang M, Mosyak L, Tam A, Duan W, Svenson K, et al. Engineering a
monomeric Fc domainmodality byN-glycosylation for the half-life extension of
biotherapeutics. J Biol Chem (2013) 288(23):16529–37. doi:10.1074/jbc.M113.
457689
33. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglob-
ulin suppresses inflammation through a novel T(H)2 pathway. Nature (2011)
475(7354):110–3. doi:10.1038/nature10134
34. Martin CC, Oeser JK, Svitek CA, Hunter SI, Hutton JC, O’Brien RM. Identi-
fication and characterization of a human cDNA and gene encoding a ubiqui-
tously expressed glucose-6-phosphatase catalytic subunit-related protein. J Mol
Endocrinol (2002) 29(2):205–22. doi:10.1677/jme.0.0290205
35. Belkaid A, Copland IB, Massillon D, Annabi B. Silencing of the human micro-
somal glucose-6-phosphate translocase induces glioma cell death: potential new
anticancer target for curcumin. FEBS Lett (2006) 580(15):3746–52. doi:10.1016/
j.febslet.2006.05.071
36. Banka S, Chervinsky E, Newman WG, Crow YJ, Yeganeh S, Yacobovich J, et al.
Further delineation of the phenotype of severe congenital neutropenia type 4
due to mutations in G6PC3. Eur J Hum Genet (2011) 19(1):18–22. doi:10.1038/
ejhg.2010.136
37. Banka S, Newman WG, Ozgul RK, Dursun A. Mutations in the G6PC3 gene
cause Dursun syndrome. Am J Med Genet A (2010) 152A(10):2609–11. doi:10.
1002/ajmg.a.33615
38. McDermott DH, De Ravin SS, JunHS, Liu Q, Priel DA, Noel P, et al. Severe con-
genital neutropenia resulting fromG6PC3 deficiency with increased neutrophil
CXCR4 expression and myelokathexis. Blood (2010) 116(15):2793–802. doi:10.
1182/blood-2010-01-265942
39. Dursun A, Ozgul RK, Soydas A, Tugrul T, Gurgey A, Celiker A, et al. Familial
pulmonary arterial hypertension, leucopenia, and atrial septal defect: a probable
new familial syndrome with multisystem involvement. Clin Dysmorphol (2009)
18(1):19–23. doi:10.1097/MCD.0b013e32831841f7
40. Boztug K, AppaswamyG, Ashikov A, Schaffer AA, Salzer U, Diestelhorst J, et al.
A syndrome with congenital neutropenia and mutations in G6PC3. N Engl J
Med (2009) 360(1):32–43. doi:10.1056/NEJMoa0805051
41. BoztugK, Rosenberg PS,DordaM, Banka S,MoultonT, Curtin J, et al. Extended
spectrum of human glucose-6-phosphatase catalytic subunit 3 deficiency: novel
genotypes and phenotypic variability in severe congenital neutropenia. J Pediatr
(2012) 160(4):679–83 e2. doi:10.1016/j.jpeds.2011.09.019
42. Chou JY, Jun HS, Mansfield BC. Neutropenia in type Ib glycogen stor-
age disease. Curr Opin Hematol (2010) 17(1):36–42. doi:10.1097/MOH.
0b013e328331df85
43. Visser G, Rake JP, Fernandes J, Labrune P, Leonard JV, Moses S, et al. Neu-
tropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen
storage disease type Ib: results of the European study on glycogen storage disease
type I. J Pediatr (2000) 137(2):187–91. doi:10.1067/mpd.2000.105232
44. Hayee B, Antonopoulos A, Murphy EJ, Rahman FZ, Sewell G, Smith BN, et al.
G6PC3 mutations are associated with a major defect of glycosylation: a novel
mechanism for neutrophil dysfunction. Glycobiology (2011) 21(7):914–24.
doi:10.1093/glycob/cwr023
45. Zhang Y, Yu X, Ichikawa M, Lyons JJ, Datta S, Lamborn IT, et al. Auto-
somal recessive phosphoglucomutase 3 (PGM3) mutations link glycosyla-
tion defects to atopy, immune deficiency, autoimmunity, and neurocognitive
impairment. J Allergy Clin Immunol (2014) 133(5): 1400–9, 9 e1–5. doi:10.1016/
j.jaci.2014.02.013
46. Sassi A, Lazaroski S, Wu G, Haslam SM, Fliegauf M, Mellouli F, et al. Hypo-
morphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair
immunity and increase serum IgE levels. J Allergy Clin Immunol (2014) 133(5):
1410–9, 9 e1–13. doi:10.1016/j.jaci.2014.02.025
47. Stray-Pedersen A, Backe PH, Sorte HS, Morkrid L, Chokshi NY, Erichsen
HC, et al. PGM3 mutations cause a congenital disorder of glycosylation with
severe immunodeficiency and skeletal dysplasia. Am J Hum Genet (2014)
95(1):96–107. doi:10.1016/j.ajhg.2014.05.007
48. Greig KT, Antonchuk J, Metcalf D, Morgan PO, Krebs DL, Zhang JG, et al.
Agm1/Pgm3-mediated sugar nucleotide synthesis is essential for hematopoiesis
and development. Mol Cell Biol (2007) 27(16):5849–59. doi:10.1128/MCB.
00802-07
49. Grunewald S. The clinical spectrum of phosphomannomutase 2 deficiency
(CDG-Ia). Biochim Biophys Acta (2009) 1792(9):827–34. doi:10.1016/j.bbadis.
2009.01.003
50. Blank C, Smith LA, Hammer DA, Fehrenbach M, Delisser HM, Perez E, et al.
Recurrent infections and immunological dysfunction in congenital disorder of
glycosylation Ia (CDG Ia). J Inherit Metab Dis (2006) 29(4):592. doi:10.1007/
s10545-006-0275-2
51. Grubenmann CE, Frank CG, Hulsmeier AJ, Schollen E, Matthijs G, Mayatepek
E, et al. Deficiency of the first mannosylation step in the N-glycosylation
pathway causes congenital disorder of glycosylation type Ik. Hum Mol Genet
(2004) 13(5):535–42. doi:10.1093/hmg/ddh050
52. Kranz C, Denecke J, Lehle L, Sohlbach K, Jeske S, Meinhardt F, et al. Congenital
disorder of glycosylation type Ik (CDG-Ik): a defect of mannosyltransferase I.
Am J Hum Genet (2004) 74(3):545–51. doi:10.1086/382493
53. Schwarz M, Thiel C, Lubbehusen J, Dorland B, de Koning T, von Figura
K, et al. Deficiency of GDP-Man:GlcNAc2-PP-dolichol mannosyltransferase
causes congenital disorder of glycosylation type Ik. Am J Hum Genet (2004)
74(3):472–81. doi:10.1086/382492
54. Dupre T, Vuillaumier-Barrot S, Chantret I, Yaye HS, Le Bizec C, Afenjar A, et al.
Guanosine diphosphate-mannose:GlcNAc2-PP-dolichol mannosyltransferase
deficiency (congenital disorders of glycosylation type Ik): five new patients and
seven novel mutations. J Med Genet (2010) 47(11):729–35. doi:10.1136/jmg.
2009.072504
55. Kranz C, Basinger AA, Gucsavas-Calikoglu M, Sun L, Powell CM, Henderson
FW, et al. Expanding spectrum of congenital disorder of glycosylation Ig (CDG-
Ig): sibs with a unique skeletal dysplasia, hypogammaglobulinemia, cardiomy-
opathy, genital malformations, and early lethality. Am J Med Genet A (2007)
143A(12):1371–8. doi:10.1002/ajmg.a.31791
Frontiers in Pediatrics | www.frontiersin.org June 2015 | Volume 3 | Article 549
Lyons et al. Glycans instructing immunity
56. De Praeter CM, Gerwig GJ, Bause E, Nuytinck LK, Vliegenthart JF, Breuer W,
et al. A novel disorder caused by defective biosynthesis of N-linked oligosaccha-
rides due to glucosidase I deficiency. Am J Hum Genet (2000) 66(6):1744–56.
doi:10.1086/302948
57. Martinez-Duncker I, Dupre T, Piller V, Piller F, Candelier JJ, Trichet C, et al.
Genetic complementation reveals a novel human congenital disorder of glyco-
sylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter.
Blood (2005) 105(7):2671–6. doi:10.1182/blood-2004-09-3509
58. Boztug K, Jarvinen PM, Salzer E, Racek T, Monch S, Garncarz W, et al.
JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital
neutropenia. Nat Genet (2014) 46(9):1021–7. doi:10.1038/ng.3069
59. Wirnsberger G, Zwolanek F, Stadlmann J, Tortola L, Liu SW, Perlot T, et al.
Jagunal homolog 1 is a critical regulator of neutrophil function in fungal host
defense. Nat Genet (2014) 46(9):1028–33. doi:10.1038/ng.3070
60. Marquardt T, Luhn K, Srikrishna G, Freeze HH, Harms E, Vestweber D.
Correction of leukocyte adhesion deficiency type II with oral fucose. Blood
(1999) 94(12):3976–85.
61. Etzioni A, Tonetti M. Fucose supplementation in leukocyte adhesion deficiency
type II. Blood (2000) 95(11):3641–3.
62. Luhn K, Marquardt T, Harms E, Vestweber D. Discontinuation of fucose
therapy in LADII causes rapid loss of selectin ligands and rise of leukocyte
counts. Blood (2001) 97(1):330–2. doi:10.1182/blood.V97.1.330
63. Hidalgo A, Ma S, Peired AJ, Weiss LA, Cunningham-Rundles C, Frenette PS.
Insights into leukocyte adhesion deficiency type 2 from a novel mutation in
the GDP-fucose transporter gene. Blood (2003) 101(5):1705–12. doi:10.1182/
blood-2002-09-2840
64. Niehues R, Hasilik M, Alton G, Korner C, Schiebe-Sukumar M, Koch HG,
et al. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose
isomerase deficiency andmannose therapy. J Clin Invest (1998) 101(7):1414–20.
doi:10.1172/JCI2350
65. Harms HK, Zimmer KP, Kurnik K, Bertele-Harms RM, Weidinger S, Reiter
K. Oral mannose therapy persistently corrects the severe clinical symptoms
and biochemical abnormalities of phosphomannose isomerase deficiency. Acta
Paediatr (2002) 91(10):1065–72. doi:10.1111/j.1651-2227.2002.tb00101.x
66. Kjaergaard S, Kristiansson B, Stibler H, Freeze HH, Schwartz M, Martinsson
T, et al. Failure of short-term mannose therapy of patients with carbohydrate-
deficient glycoprotein syndrome type 1A. Acta Paediatr (1998) 87(8):884–8.
doi:10.1111/j.1651-2227.1998.tb01556.x
67. Tegtmeyer LC, Rust S, van Scherpenzeel M, Ng BG, Losfeld ME, Timal S, et al.
Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med (2014)
370(6):533–42. doi:10.1056/NEJMoa1206605
68. Chu VC, Whittaker GR. Influenza virus entry and infection require host cell
N-linked glycoprotein. Proc Natl Acad Sci U S A (2004) 101(52):18153–8.
doi:10.1073/pnas.0405172102
69. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC,
Middel J, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that
enhances trans-infection of T cells. Cell (2000) 100(5):587–97. doi:10.1016/
S0092-8674(00)80694-7
70. Ahmed SP, Nash RJ, Bridges CG, Taylor DL, KangMS, Porter EA, et al. Antiviral
activity andmetabolism of the castanospermine derivativeMDL 28,574, in cells
infected with herpes simplex virus type 2. Biochem Biophys Res Commun (1995)
208(1):267–73. doi:10.1006/bbrc.1995.1333
71. Fischer PB, Karlsson GB, Dwek RA, Platt FM. N-butyldeoxynojirimycin-
mediated inhibition of human immunodeficiency virus entry correlates with
impaired gp120 shedding and gp41 exposure. J Virol (1996) 70(10):7153–60.
72. Qu X, Pan X, Weidner J, Yu W, Alonzi D, Xu X, et al. Inhibitors of endoplasmic
reticulum alpha-glucosidases potently suppress hepatitis C virus virion assem-
bly and release. Antimicrob Agents Chemother (2011) 55(3):1036–44. doi:10.
1128/AAC.01319-10
73. Fischl MA, Resnick L, Coombs R, Kremer AB, Pottage JC Jr, Fass RJ, et al. The
safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and
zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J
Acquir Immune Defic Syndr (1994) 7(2):139–47.
74. Gantt S, Gachelet E, Carlsson J, Barcy S, Casper C, Lagunoff M. Nelfinavir
impairs glycosylation of herpes simplex virus 1 envelope proteins and blocks
virus maturation. Adv Virol (2015) 2015:687162. doi:10.1155/2015/687162
75. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old
bottle. Proc Natl Acad Sci U S A (2002) 99(16):10231–3. doi:10.1073/pnas.
172380699
76. Mkhikian H, Grigorian A, Li CF, Chen HL, Newton B, Zhou RW, et al. Genet-
ics and the environment converge to dysregulate N-glycosylation in multiple
sclerosis. Nat Commun (2011) 2:334. doi:10.1038/ncomms1333
77. Guevara J, Espinosa B, Zenteno E, Vazguez L, Luna J, Perry G, et al. Altered
glycosylation pattern of proteins inAlzheimer disease. J Neuropathol ExpNeurol
(1998) 57(10):905–14. doi:10.1097/00005072-199810000-00003
78. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood (2014)
124(18):2804–11. doi:10.1182/blood-2014-02-522128
79. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Gly-
cosylation changes of IgG associated with rheumatoid arthritis can activate
complement via the mannose-binding protein. Nat Med (1995) 1(3):237–43.
doi:10.1038/nm0395-237
80. Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy (IgAN).Kidney
Int (2004) 65(5):1544–7. doi:10.1111/j.1523-1755.2004.05407.x
81. Janssen MJ, Waanders E, Woudenberg J, Lefeber DJ, Drenth JP. Congenital
disorders of glycosylation in hepatology: the example of polycystic liver disease.
J Hepatol (2010) 52(3):432–40. doi:10.1016/j.jhep.2009.12.011
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Lyons, Milner and Rosenzweig. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pediatrics | www.frontiersin.org June 2015 | Volume 3 | Article 5410
